nach oben

Journal of Neuro-Oncology

Erschienen in:

27.09.2021 | Clinical Study

Psychological resiliency explains the relationship between emotional distress and quality of life in neurofibromatosis

verfasst von: Ryan A. Mace, James Doorley, Jafar Bakhshaie, Joshua E. Cohen, Ana-Maria Vranceanu

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Neurofibromatoses (NF; NF1, NF2, and schwannomatosis) are incurable tumor suppressor syndromes with heterogeneous symptoms. Emotional distress (e.g., depression, anxiety, stress) is common in NF and impairs quality of life (QoL). Several modifiable dimensions of resiliency can contribute to enhanced QoL in medical populations but have been overlooked as treatment mechanisms for NF. Our goal was to determine, using data from an ongoing efficacy RCT testing a mind–body program for NF, if resiliency explains the relationship between emotional distress and QoL.

Methods

We performed structural equation modeling mediation analysis on baseline measures of QoL (physical health, psychological, social relationships, environmental), emotional distress (depression, anxiety, stress), and resiliency (gratitude, optimism, coping, mindfulness, empathy) completed by adults with NF (N = 228). We controlled for variables known to impact psychosocial functioning in NF (age, diagnosis, learning disability, and education).

Results

After adjusting for covariates, resiliency had a significant and large indirect effect on the negative relationship between emotional distress and QoL (CSIE = − 0.31, 95% CI = − 0.59 to − 0.19, p = .001). The direct effect of emotional distress on QoL was smaller but remained significant (β = − 0.23, 95% CI = − 0.44 to − 0.03, p = .03), suggesting partial mediation through resiliency.

Conclusions

Resiliency may buffer the high rates of emotional distress in NF. Mind–body interventions targeting multiple modifiable resiliency factors may be a promising path toward promoting QoL in adults with NF.

Trial registration

Clinical Trials.gov Identifier: NCT03406208.

Friedman JM (1999) Epidemiology of neurofibromatosis type 1. Am J Med Genet 89(1):1–6CrossRefPubMed

Jouhilahti E-M, Peltonen S, Heape AM, Peltonen J (2011) The pathoetiology of neurofibromatosis 1. Am J Pathol 178(5):1932–1939. https://doi.org/10.1016/j.ajpath.2010.12.056CrossRefPubMedPubMedCentral

Evans D (1993) Neurofibromatosis 2. In: Adam M, Ardinger H, Pagon R, et al. (eds) Genereviews. https://scholar.google.com/scholar_lookup?title=GeneReviews&author=DG+Evans&publication_year=1993&

Hilton DA, Hanemann CO (2014) Schwannomas and their pathogenesis: schwannomas and their pathogenesis. Brain Pathol 24(3):205–220. https://doi.org/10.1111/bpa.12125CrossRefPubMedPubMedCentral

Lin AL, Gutmann DH (2013) Advances in the treatment of neurofibromatosis-associated tumours. Nat Rev Clin Oncol 10(11):616–624. https://doi.org/10.1038/nrclinonc.2013.144CrossRefPubMed

Vranceanu A-M, Merker VL, Park E, Plotkin SR (2013) Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol 114(3):257–262. https://doi.org/10.1007/s11060-013-1195-2CrossRefPubMed

Wang DL, Smith KB, Esparza S et al (2012) Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome. Genet Med 14(12):977–982. https://doi.org/10.1038/gim.2012.85CrossRefPubMedPubMedCentral

Sanagoo A, Jouybari L, Koohi F, Sayehmiri F (2019) Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study. BMC Neurol 19(1):123. https://doi.org/10.1186/s12883-019-1338-yCrossRefPubMedPubMedCentral

Rietman AB, van Helden H, Both PH et al (2018) Worries and needs of adults and parents of adults with neurofibromatosis type 1. Am J Med Genet A 176(5):1150–1160. https://doi.org/10.1002/ajmg.a.38680CrossRefPubMedPubMedCentral

10.

Cosetti MK, Golfinos JG, Roland JT (2015) Quality of life (QoL) assessment in patients with neurofibromatosis type 2 (NF2). Otolaryngol Neck Surg 153(4):599–605. https://doi.org/10.1177/0194599815573002CrossRef

11.

Graf A, Landolt MA, Mori AC, Boltshauser E (2006) Quality of life and psychological adjustment in children and adolescents with neurofibromatosis type 1. J Pediatr 149(3):348–353. https://doi.org/10.1016/j.jpeds.2006.04.025CrossRefPubMed

12.

Hamoy-Jimenez G, Kim R, Suppiah S, Zadeh G, Bril V, Barnett C (2020) Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. Neuro-Oncol Adv 2(Supplement_1):i141-i149. https://doi.org/10.1093/noajnl/vdaa003

13.

Simon MK (2005) Meaning, coping and life satisfaction among individuals with neurofibromatosis type-1 (NF1).

14.

Bonanno GA, Galea S, Bucciarelli A, Vlahov D (2007) What predicts psychological resilience after disaster? The role of demographics, resources, and life stress. J Consult Clin Psychol 75(5):671–682. https://doi.org/10.1037/0022-006X.75.5.671CrossRefPubMed

15.

Ovaska-Stafford N, Maltby J, Dale M (2021) Literature review: psychological resilience factors in people with neurodegenerative diseases. Arch Clin Neuropsychol 36(2):283–306. https://doi.org/10.1093/arclin/acz063CrossRefPubMed

16.

Zale EL, Heinhuis TJ, Tehan T, Salgueiro D, Rosand J, Vranceanu A-M (2018) Resiliency is independently associated with greater quality of life among informal caregivers to neuroscience intensive care unit patients. Gen Hosp Psychiatry 52:27–33. https://doi.org/10.1016/j.genhosppsych.2018.02.012CrossRefPubMed

17.

Zale EL, Pierre-Louis C, Macklin EA, Riklin E, Vranceanu A-M (2018) The impact of a mind–body program on multiple dimensions of resiliency among geographically diverse patients with neurofibromatosis. J Neurooncol 137(2):321–329. https://doi.org/10.1007/s11060-017-2720-5CrossRefPubMed

18.

Holland JN, Schmidt AT (2015) Static and dynamic factors promoting resilience following traumatic brain injury: a brief review. Neural Plast 2015:1–8. https://doi.org/10.1155/2015/902802CrossRef

19.

Granström S, Friedrich RE, Langenbruch AK, Augustin M, Mautner V-F (2014) Influence of learning disabilities on the tumour predisposition syndrome NF1–survey from adult patients’ perspective. Anticancer Res 34(7):3675–3681PubMed

20.

Park ER, Traeger L, Vranceanu A-M et al (2013) The development of a patient-centered program based on the relaxation response: the relaxation response resiliency program (3RP). Psychosomatics 54(2):165–174. https://doi.org/10.1016/j.psym.2012.09.001CrossRefPubMed

21.

Vranceanu A-M, Zale EL, Funes CJ et al (2018) Mind-body treatment for international english-speaking adults with neurofibromatosis via live videoconferencing: protocol for a single-blind randomized controlled trial. JMIR Res Protoc 7(10):e11008. https://doi.org/10.2196/11008CrossRefPubMedPubMedCentral

22.

Skevington SM, Lotfy M, O’Connell KA (2004) The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A Report from the WHOQOL Group. Qual Life Res 13(2):299–310. https://doi.org/10.1023/B:QURE.0000018486.91360.00

23.

Kroenke K, Spitzer RL, Williams JBW (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16(9):606–613. https://doi.org/10.1046/j.1525-1497.2001.016009606.xCrossRefPubMedPubMedCentral

24.

Williams KG, Sanderson M, Jette N, Patten SB (2020) Validity of the patient health questionnaire-9 in neurologic populations. Neurol Clin Pract 10(3):190–198. https://doi.org/10.1212/CPJ.0000000000000748CrossRefPubMedPubMedCentral

25.

Spitzer RL, Kroenke K, Williams JBW, Löwe B (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166(10):1092. https://doi.org/10.1001/archinte.166.10.1092CrossRefPubMed

26.

Johnson SU, Ulvenes PG, Øktedalen T, Hoffart A (2019) Psychometric properties of the general anxiety disorder 7-item (GAD-7) scale in a heterogeneous psychiatric sample. Front Psychol 10:1713. https://doi.org/10.3389/fpsyg.2019.01713CrossRefPubMedPubMedCentral

27.

Cohen S, Kamarck T, Mermelstein R (1983) A global measure of perceived stress. J Health Soc Behav 24(4):385. https://doi.org/10.2307/2136404CrossRefPubMed

28.

Lee E-H (2012) Review of the psychometric evidence of the Perceived Stress Scale. Asian Nurs Res 6(4):121–127. https://doi.org/10.1016/j.anr.2012.08.004CrossRef

29.

Windle G, Bennett KM, Noyes J (2011) A methodological review of resilience measurement scales. Health Qual Life Outcomes 9:8. https://doi.org/10.1186/1477-7525-9-8CrossRefPubMedPubMedCentral

30.

Vranceanu A-M, Riklin E, Merker VL, Macklin EA, Park ER, Plotkin SR (2016) Mind–body therapy via videoconferencing in patients with neurofibromatosis: an RCT. Neurology 87(8):806–814. https://doi.org/10.1212/WNL.0000000000003005CrossRefPubMed

31.

McCullough ME, Emmons RA, Tsang J-A (2002) The grateful disposition: a conceptual and empirical topography. J Pers Soc Psychol 82(1):112–127. https://doi.org/10.1037/0022-3514.82.1.112CrossRefPubMed

32.

Cousin L, Redwine L, Bricker C, Kip K, Buck H (2020) Psychometrics of the gratitude questionnaire-6 in African-Americans at risk for cardiovascular disease. West J Nurs Res 42(12):1148–1154. https://doi.org/10.1177/0193945920922777CrossRefPubMed

33.

Scheier MF, Carver CS (1985) Optimism, coping, and health: assessment and implications of generalized outcome expectancies. Health Psychol 4(3):219–247. https://doi.org/10.1037/0278-6133.4.3.219CrossRefPubMed

34.

Chiesi F, Galli S, Primi C, Innocenti Borgi P, Bonacchi A (2013) The accuracy of the life orientation test-revised (LOT–R) in measuring dispositional optimism: evidence from item response theory analyses. J Pers Assess 95(5):523–529. https://doi.org/10.1080/00223891.2013.781029CrossRefPubMed

35.

Carver C (2006) Measure of current status. http://www.psy.miami.edu/faculty/ccarver/sclMOCS.html

36.

Antoni MH, Lechner SC, Kazi A et al (2006) How stress management improves quality of life after treatment for breast cancer. J Consult Clin Psychol 74(6):1143–1152. https://doi.org/10.1037/0022-006X.74.6.1143CrossRefPubMedPubMedCentral

37.

Feldman G, Hayes A, Kumar S, Greeson J, Laurenceau J-P (2007) Mindfulness and emotion regulation: the development and initial validation of the cognitive and affective mindfulness scale-revised (CAMS-R). J Psychopathol Behav Assess 29(3):177–190. https://doi.org/10.1007/s10862-006-9035-8CrossRef

38.

Hayes AF (2013) Introduction to mediation, moderation, and conditional process analysis: a regression-based approach. The Guilford Press

39.

Ludolph P, Kunzler AM, Stoffers-Winterling J, Helmreich I, Lieb K (2019) Interventions to promote resilience in cancer patients. Dtsch Aerzteblatt. https://doi.org/10.3238/arztebl.2019.0865

40.

Campbell P, Bishop A, Dunn KM, Main CJ, Thomas E, Foster NE (2013) Conceptual overlap of psychological constructs in low back pain. Pain 154(9):1783–1791. https://doi.org/10.1016/j.pain.2013.05.035CrossRefPubMedPubMedCentral

Titel: Psychological resiliency explains the relationship between emotional distress and quality of life in neurofibromatosis
verfasst von: Ryan A. Mace
James Doorley
Jafar Bakhshaie
Joshua E. Cohen
Ana-Maria Vranceanu
Publikationsdatum: 27.09.2021
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2021
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-021-03852-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Trial registration

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Prognosticating survival of pineal parenchymal tumors of intermediate differentiation (PPTID) by grade

Systemic coagulation is activated in patients with meningioma and glioblastoma

Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial

Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies

Incidence and survival for childhood central nervous system tumours in Australia, 1983–2016